4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:August 23, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing Post author:andrewkaretas Post published:August 21, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
10-Q: Quarterly report which provides a continuing view of a company’s financial position Post author:andrewkaretas Post published:August 7, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading10-Q: Quarterly report which provides a continuing view of a company’s financial position
8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:August 7, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 20, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing Post author:andrewkaretas Post published:June 18, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
3: Initial filing by director officer or owner of more than ten percent Post author:andrewkaretas Post published:June 11, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading3: Initial filing by director officer or owner of more than ten percent
8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:June 10, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 7, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 7, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
